bioAffinity Technologies, Inc.

BIAF Healthcare Diagnostics & Research

In the quarter to June 2026, revenue grew 19.0%, EPS grew 87.5%, free cash flow fell 23.7% and total debt rose 569.7%, each against the same quarter a year earlier.

3.73 0.23 −5.81%
Market cap
$5.1M
P/E
0.0×
Fwd P/E
−0.2×
Dividend yield
—
F-score
2/9
Altman Z
−10.54
Beneish M
−5.49
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
0.72 3.04 0.33 0.47
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(1.33) (5.34) (0.79) (1.27)
P/B ratio
1.13 4.70 0.28 0.35
EV/Sales
0.40 2.60 (0.61) (0.64)
EV/EBITDA
0.00 0.00 0.37 0.44
EV/FCF
(0.21) (1.35) 0.40 0.51
Current Ratio
1.44 1.36 2.60 3.65
Net Debt/EBITDA
0.57 0.71 1.92 3.44
Debt/Equity
0.15 0.17 0.09 0.02
Earnings Yield
(898.56%) (307.03%) (1,334.92%) (707.62%)
Free Cash Flow Yield
(272.26%) (63.46%) (462.09%) (269.48%)
Free Cash Flow per Share
(9.44) (10.78) (22.30) (34.83)
Book value per Share
10.81 12.21 63.39 125.21
Free Cash Flow
(3.29) (3.23) (2.56) (2.48)
EV/EBIT
0.00 0.00 0.35 0.42
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026